BCL2 and cancer: Using msEVs loaded with siRNAs targeting VEGF, EGF, AKT, MAPK, and KRAS, it showed a 2- to 10-fold decrease in the expression levels of the corresponding targets in various cancers [171], as shown in Figure 6B. When Bcl-2 siRNA was loaded into msEVs using an ultrasonic technique, both in vitro and in vivo cancer cell migration and the formation of gastrointestinal tumors were significantly suppressed [173].